| Literature DB >> 29654499 |
Gabriel Bernardes1, Richard G IJzerman2, Jennifer S Ten Kulve2, Frederik Barkhof3,4, Michaela Diamant2, Dick J Veltman5, Jesus Landeira-Fernandez1, Liselotte van Bloemendaal2, Eelco van Duinkerken6,7,8,9.
Abstract
Type 2 diabetes (T2DM) is associated with structural cortical and subcortical alterations, although it is insufficiently clear if these alterations are driven by obesity or by diabetes and its associated complications. We used FreeSurfer5.3 and FSL-FIRST to determine cortical thickness, volume and surface area, and subcortical gray matter volume in a group of 16 normoglycemic obese subjects and 28 obese T2DM patients without clinically manifest micro- and marcoangiopathy, and compared them to 31 lean normoglycemic controls. Forward regression analysis was used to determine demographic and clinical correlates of altered (sub)cortical structure. Exploratively, vertex-wise correlations between cortical structure and fasting glucose and insulin were calculated. Compared with controls, obese T2DM patients showed lower right insula thickness and lower left lateral occipital surface area (PFWE < 0.05). Normoglycemic obese versus controls had lower thickness (PFWE < 0.05) in the right insula and inferior frontal gyrus, and higher amygdala and thalamus volume. Thalamus volume and left paracentral surface area were also higher in this group compared with obese T2DM patients. Age, sex, BMI, fasting glucose, and cholesterol were related to these (sub)cortical alterations in the whole group (all P < 0.05). Insulin were related to temporal and frontal structural deficits (all PFWE < 0.05). Parietal/occipital structural deficits may constitute early T2DM-related cerebral alterations, whereas in normoglycemic obese subjects, regions involved in emotion, appetite, satiety regulation, and inhibition were affected. Central adiposity and elevated fasting glucose may constitute risk factors.Entities:
Keywords: Brain structure; Glucose; Insulin; Neuroimaging; Obesity; Type 2 diabetes
Mesh:
Substances:
Year: 2018 PMID: 29654499 PMCID: PMC6060745 DOI: 10.1007/s11011-018-0223-5
Source DB: PubMed Journal: Metab Brain Dis ISSN: 0885-7490 Impact factor: 3.584
Participant characteristics
| Controls | Obese | Type 2 diabetes | ||
|---|---|---|---|---|
| Age (years) | 57.08 ± 7.10 | 58.01 ± 8.39 | 60.44 ± 5.05 | 0.158 |
| Sex, male/female (% male) | 16/15 (51.6) | 8/8 (50) | 15/13 (53.6) | 0.999 |
| Diabetes duration (years) | – | – | 8.15 ± 4.81 | – |
| BMI (kg/m2) | 22.96 ± 1.64 | 32.58 ± 2.86a | 32.25 ± 4.51a | <0.001 |
| Systolic blood pressure (mmHg) | 118.32 ± 16.17 | 126.75 ± 12.08 | 135.31 ± 13.11a | <0.001 |
| Diastolic blood pressure (mmHg) | 74.60 ± 10.51 | 79.14 ± 7.73 | 81.00 ± 8.84a | 0.033 |
| Antihypertensive medication use (%) | 0 (0) | 3 (18.8) | 17 (60.7)a, b | <0.001 |
| Hypertension (%)c | 5 (16.1) | 4 (25) | 18 (64.3)a, b | <0.001 |
| HbA1c (%) | 5.61 ± 0.36 | 5.58 ± 0.27 | 6.99 ± 1.05a, b | <0.001 |
| HbA1c (mmol/mol) | 37.24 ± 1.57 | 37.62 ± 3.03 | 53.46 ± 10.74a, b | <0.001 |
| Total cholesterol (mmol/L) | 5.43 ± 0.89 | 5.66 ± 0.89 | 4.55 ± 1.38a, b | 0.002 |
| HDL cholesterol (mmol/L) | 1.91 ± 0.48 | 1.42 ± 0.43 | 1.17 ± 0.33a | <0.001 |
| LDL cholesterol (mmol/L) | 3.13 ± 0.80 | 3.45 ± 0.69 | 2.39 ± 0.92a, b | <0.001 |
| Triglycerides (mmol/L) | 0.91 ± 0.41 | 1.76 ± 1.31a | 1.66 ± 1.01a | 0.002 |
| Cholesterol medication use (%) | 0 (0) | 1 (6.3) | 19 (67.9)a, b | <0.001 |
| Fasting plasma glucose (mmol/L) | 4.85 ± 0.56 | 5.27 ± 0.41 | 8.50 ± 2.31a, b | <0.001 |
| Fasting insulin (pmol/L) | 37.56 ± 18.75 | 83.62 ± 51.25a | 90.77 ± 35.42a | <0.001 |
| Estimated intracranial volume (mL) | 1547 ± 127.70 (1352–1768) | 1505 ± 173.35 (1266–1874) | 1473 ± 143.67 (1272–1884) | 0.149 |
| Manual edits (%) | 8 (25.8) | 5 (31.3) | 10 (35.7) | 0.729 |
| Control pointsd | 1 | 0 | 0 | – |
| Brain editinge | 7 | 5 | 10 | – |
Data are presented as mean with standard deviation or absolute number with percentage between parentheses. The P-value represents the P-value of the overall F-test
adifferent from controls
bdifferent from obese
cHypertension was defined as a systolic blood pressure of 140 mmHg or above, a diastolic blood pressure of 90 mmHg or above, or the use of antihypertensive medication
dAdding control point in the white matter to push the white matter segmentation forward
eBrain editing consisting of removing excessive skull or changing the intensity of voxels that were wrongly labeled
Values of whole brain indices of cortical structure and subcortical volume
| Controls | Normoglycemic obese | Type 2 diabetes | ||
|---|---|---|---|---|
| Cortical thickness (mm) | ||||
| Whole brain | 2.47 ± 0.08 | 2.43 ± 0.08 | 2.43 ± 0.08 | 0.368 |
| Left hemisphere | 2.47 ± | 2.44 ± 0.08 | 2.43 ± 0.09 | 0.313 |
| Right hemisphere | 2.46 ± 0.09 | 2.43 ± 0.08 | 2.43 ± 0.08 | 0.439 |
| Cortical surface area (mm2) | ||||
| Whole brain | 2511.09 ± 221.00 | 2435.03 ± 318.07 | 2398.78 ± 248.28 | 0.951 |
| Left hemisphere | 2507.86 ± 219.64 | 2436.05 ± 310.31 | 2397.12 ± 250.98 | 0.973 |
| Right hemisphere | 2514.31 ± 224.07 | 2434.00 ± 326.67 | 2400.44 ± 246.41 | 0.909 |
| Cortical volume (mL) | ||||
| Whole brain | 465.38 ± 43.61 | 449.97 ± 62.22 | 439.65 ± 35.27 | 0.833 |
| Left hemisphere | 233.22 ± 22.42 | 225.22 ± 30.57 | 219.98 ± 17.20 | 0.743 |
| Right hemisphere | 232.17 ± 21.52 | 224.74 ± 31.73 | 219.67 ± 18.38 | 0.911 |
| Subcortical volume (mL)e | ||||
| Bilateral amygdala | 1.86 ± 0.29 | 2.17 ± 0.25a | 2.01 ± 0.23 | 0.001 |
| Bilateral thalamus | 10.16 ± 0.72 | 10.66 ± 0.57a, c | 10.04 ± 0.63 | 0.010 |
| Bilateral caudate nucleus | 4.65 ± 0.47 | 4.61 ± 0.32 | 4.59 ± 0.36 | 0.871 |
| Bilateral putamen | 6.41 ± 0.71 | 6.45 ± 0.57 | 6.24 ± 0.58 | 0.833 |
| Bilateral pallidum | 2.35 ± 0.21 | 2.44 ± 0.15 | 2.35 ± 0.17 | 0.174 |
| Bilateral hippocampus | 5.10 ± 0.52 | 5.31 ± 0.39 | 5.17 ± 0.46 | 0.305 |
| Bilateral nucleus accumbens | 0.63 ± 0.13 | 0.61 ± 0.08 | 0.60 ± 0.12 | 0.962 |
Data are presented as mean with standard deviation. The P-value represents the overall P-value of the F-test
adifferent from controls
bdifferent from obese
cdifferent from type 2 diabetes
dAnalyses of cortical thickness, surface area and volume are corrected for age, sex, hypertension and estimated total intracranial volume. Subcortical analyses were corrected for age, sex and hypertension only
eSubcortical volume was corrected for head size by multiplying the participant’s subcortical volume by its own V-scaling factor, obtained by FSL-SIENAX
Fig. 1Clusters of lower cortical gray matter surface indices overlaid on a standard brain for right cortical thickness, left panel, and left surface area, right panel. Red-Yellow indicate the positive group effect, whereas blue-light blue indicates a negative effect
Information of between-group vertex-wise analyses and whole group vertex-wise correlation analyses
| Cluster size (mm2) | Peak t-value | MNI coordinates peak value (x, y, z) | Anatomical location | ||
|---|---|---|---|---|---|
| Right cortical thickness | |||||
| Cluster group effect | 537.38 | 4.347 | 34.0, −11.1, 16.3 | Insula / transverse temporal / superior temporal / supramarginal / precentral | 0.024 |
| Cluster T2DM lower than controls | 571.43 | 4.720 | 34.1, −10.3, 16.1 | Insula / transverse temporal / superior temporal / supramarginal / precentral | 0.017 |
| Cluster obese lower than controls | 556.05 | 3.380 | 37.9, −34.4, 12.5 | Insula / transverse temporal / superior temporal / supramarginal / precentral / pars opercularis | 0.019 |
| Left surface area | |||||
| Cluster group effect | 678.51 | 2.892 | −12.7, −95.2, 20.0 | Lateral occipital / superior parietal / cuneus | 0.063 |
| Cluster T2DM lower than controls | 972.56 | 3.478 | −13.3, −94.9, 20.3 | Lateral occipital / superior parietal / cuneus | 0.007 |
| Cluster T2DM lower than obese | 748.11 | 4.890 | −6.9, −19.6, 67.0 | Paracentral | 0.040 |
| Whole group insulin | |||||
| Cluster 1 left area negative | 2008.94 | −4.278 | −23.6, 49.2, 9.6 | Rostral middle frontal / superior frontal | 0.0002 |
| Cluster 2 left area negative | 1373.58 | −2.697 | −64.1, −31.9, 8.5 | Superior temporal / supramarginal / banks of the superior temporal sulcus | 0.0008 |
| Cluster 1 left volume negative | 951.04 | −2.831 | −58.7, −51.3, 22.2 | Superior temporal / supramarginal / banks of the superior temporal sulcus | 0.001 |
| Cluster 2 left volume negative | 599.10 | −3.057 | −35.9, −17.2, 7.4 | Insula / transverse temporal | 0.020 |
| Cluster 1 left thickness positive | 491.43 | 4.212 | −7.3, 35.2, −22.7 | Medial orbitofrontal / lateral orbitofrontal | 0.040 |
Fig. 2Scatter plot of the correlations between clusters of altered cortical structure and medical and anthropometric variables. Green circles depict the healthy lean controls, blue triangles the normoglycemic obese, and red squares the obese T2DM patients. The black regression line shows the correlation for the whole group. The colored regression lines depict the correlation for either the normoglycemic obese (blue) or obese T2DM (red) participants. The correlation with sex is presented as mean with standard deviation and represents men and women irrespective or group allocation
Fig. 3Scatter plot of the correlations between altered subcortical structures and medical and anthropometric variables. Green circles depict the healthy lean controls, blue triangles the normoglycemic obese, and red squares the obese T2DM patients. The black regression line shows the correlation for the whole group. The colored regression lines depict the correlation for either the normoglycemic obese (blue) or obese T2DM (red) participants. The correlation with sex is presented as mean with standard deviation and represents men and women irrespective or group allocation
Fig. 4Schematic representation of the clusters where insulin, was significantly negatively related to either, surface area, thickness, or volume in all participants. Blue-light blue indicates a negative correlation, whereas red-yellow indicates a positive correlation
Fig. 5Scatter plot of the correlations between clusters that showed a vertex-wise correlation with insulin. Green circles depict the healthy lean controls, blue triangles the normoglycemic obese, and red squares the obese T2DM patients. The black regression line shows the correlation for the whole group. The colored regression lines depict the correlation for either the normoglycemic obese (blue) or obese T2DM (red) participants